← Back to Home

Cord Blood Cell Therapy Omisirge Approved for Blood Cancer Transplantation, With Shortening the Immune Window Becoming a Treatment Focus

For blood cancer patients receiving cord blood transplantation, the most dangerous moment is often not the infusion itself, but the waiting period before the immune system has been rebuilt; Omisirge’s approval pushes cell-processing technology to the clinical front line of reducing infection risk.

By SURL BioNews

After blood cancer patients undergo intensive conditioning and cord blood transplantation, the body passes through a vulnerable period with almost no adequate white blood cell defenses. The longer this immune window lasts, the higher the risk of bacterial and fungal infections, forcing a treatment originally intended to rebuild the hematopoietic system to also confront the pressure of transplant complications.

Omisirge (omidubicel-onlv), approved by the U.S. Food and Drug Administration (FDA), is aimed precisely at this clinical bottleneck. FDA documents show that the therapy is indicated for adults and pediatric patients 12 years of age and older with hematologic malignancies who are planned for cord blood transplantation following myeloablative conditioning, with the aim of shortening the time to neutrophil recovery and reducing the incidence of infection.

Omisirge is not a conventional small-molecule drug, but a substantially modified allogeneic cord blood-derived cell therapy. Its manufacturing process is based on human donor cord blood hematopoietic stem cells, which are cultured and processed with nicotinamide before being administered to patients as a single intravenous infusion. In other words, it seeks to make cord blood transplantation not only a matter of “finding usable cells,” but also of enabling those cells to engraft and complete immune reconstitution more quickly in the recipient’s body.

In its approval materials, the FDA cited a randomized, multicenter study: among patients who received Omisirge, the median time to neutrophil recovery was 12 days, compared with 22 days in the standard cord blood transplant group; by Day 100, the incidence of bacterial or fungal infection was 39% and 60%, respectively. These figures show that the focus of the approval is not a claim to cure blood cancer, but to improve the riskiest early clinical course after transplantation.

However, the risks of cell therapy do not disappear because of efficacy signals. The Omisirge label includes boxed warnings, including infusion reactions, graft-versus-host disease, engraftment syndrome, and graft failure. These warnings remind clinicians that shortening the time to immune recovery does not mean transplant risks have been fully eliminated; patient selection, monitoring, and the experience of the transplant team remain key to whether the treatment can be implemented safely.

It is worth clarifying that the latest media summary only briefly mentioned FDA approval of a donor immune cell therapy to reduce transplant complications in blood cancer patients; FDA public documents show that Omisirge’s biologics approval date was April 17, 2023, while the product page in 2026 still lists its official name, manufacturer Gamida Cell Ltd., and indication. If this report is a republication or data update, the currently available public summary does not provide new clinical trial results or an expanded indication.

The significance of this approval lies in the long-standing problems faced by cord blood transplantation, including limited cell quantity, slower engraftment, and a relatively high risk of infection. Omisirge brings ex vivo processing and expansion of cord blood cells into a formal regulatory framework, providing another option for patients with hematologic tumors who cannot obtain a suitable adult donor; but it also pushes the issue to the next level: whether the cell product can be manufactured consistently, supplied in time, and maintain consistent safety and efficacy across different transplant centers.

References

  1. Gulf Coast Media
  2. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration
  4. U.S. Food and Drug Administration
  5. U.S. Food and Drug Administration